Dr Sara Busacca

Research Fellow

Room 411, Hodgkin Building,Dr Busacca
Leicester LE1 9HN
Tel: +44 (0) 116 252 5591
Email: sb580@le.ac.uk

Personal details

  • 2006: Master Degree in Chemistry and Pharmaceutical Technologies. University of Piemonte Orientale Amedeo Avogadro, Italy
  • 2006: Pharmacist qualification
  •  2007- 2009: PhD in Food and Pharmaceutical Biotechnology, University of Piemonte Orientale Amedeo Avogadro, Italy
  • 2009-2010 Research fellow, University of Piemonte Orientale, Italy
  • 2010-March 2012: Post-Doctoral research fellow, Queen’s University of Belfast, Northern Ireland
  • 2012- Present: Research associate, University of Leicester, UK

List of publications:


https://www.ncbi.nlm.nih.gov/pubmed/?term=busacca+s

Research:

I have a particular interest in in understanding the molecular mechanisms that determine response to therapy in relapsed mesothelioma.

My current projects are focused on:

  • Genomic instability and markers of immune escape
  • BRCA1 as biomarker of response to spindle poisons
  • Synthetic lethal targeting of MTAP

In these studies, we use a combination of standard molecular biology technologies, patient samples, ex vivo models (explants), 3D cultures isolated from pleural fluids and next-generation sequencing.

External relationships:

  • 2016: Member of the local organizing committee for IMIG (International Mesothelioma Interest Group)
  • 2017: Member of the ECMC JING (junior investigators network group) steering committee

Share this page:

NEWS

Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform

---------------------------------

SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.